Paterson Anna L, Fitzgerald Rebecca C
MRC Cancer Cell Unit, Hutchison-MRC Research Centre, Hills Road, Cambridge, CB2 0XZ, UK +44 1223 763287 ; +44 1223 763296 ;
Expert Opin Med Diagn. 2007 Nov;1(3):363-76. doi: 10.1517/17530059.1.3.363.
Barrett's oesophagus is a well-recognised premalignant lesion for oesophageal adenocarcinoma. It is present in 1 - 2% of the general population, and 2 - 5% of those with gastro-oesophageal reflux disease. The majority of Barrett's cases within the population are undiagnosed, consequently most cases of oesophageal adenocarcinoma arise de novo. The incidence of oesophageal adenocarcinoma has increased by more than sixfold in the last 30 years. However, most patients with Barrett's oesophagus will not develop oesophageal adenocarcinoma. The major focus of biomarker research in Barrett's oesophagus is to find a marker that is able to identify patients at the highest risk of progressing to adenocarcinoma. Other potential roles include increasing the sensitivity of minimally invasive screening tests to identify patients with Barrett's oesophagus and predicting which patients are most likely to benefit from chemoprevention and endoscopic therapies. In established oesophageal adenocarcinoma, biomarkers would be able to individualise patient management by providing valuable information on patient prognosis and their suitability for novel targeted therapies. This review aims to explore the potential roles of biomarkers in Barrett's oesophagus and oesophageal adenocarcinoma, focusing on the most extensively studied candidates and future novel developments.
巴雷特食管是一种公认的食管腺癌癌前病变。它在普通人群中的发生率为1% - 2%，在胃食管反流病患者中的发生率为2% - 5%。人群中大多数巴雷特食管病例未被诊断出来，因此大多数食管腺癌病例是新发的。在过去30年中，食管腺癌的发病率增加了六倍多。然而，大多数巴雷特食管患者不会发展为食管腺癌。巴雷特食管生物标志物研究的主要重点是找到一种能够识别进展为腺癌风险最高的患者的标志物。其他潜在作用包括提高微创筛查试验的敏感性以识别巴雷特食管患者，以及预测哪些患者最有可能从化学预防和内镜治疗中获益。在已确诊的食管腺癌中，生物标志物能够通过提供有关患者预后及其对新型靶向治疗适用性的有价值信息，实现患者管理的个体化。本综述旨在探讨生物标志物在巴雷特食管和食管腺癌中的潜在作用，重点关注研究最广泛的候选标志物和未来的新进展。
